A detailed history of Kbc Group Nv transactions in Charles River Laboratories International, Inc. stock. As of the latest transaction made, Kbc Group Nv holds 84,566 shares of CRL stock, worth $15.9 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares
84,566
Previous 134,885 37.31%
Holding current value
$15.9 Million
Previous $27.9 Million 40.22%
% of portfolio
0.05%
Previous 0.08%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024

SELL
$187.96 - $245.29 $9.46 Million - $12.3 Million
-50,319 Reduced 37.31%
84,566 $16.7 Million
Q2 2024

Jul 17, 2024

SELL
$206.39 - $268.73 $152,934 - $199,128
-741 Reduced 0.55%
134,885 $27.9 Million
Q1 2024

May 08, 2024

SELL
$203.52 - $273.43 $16.3 Million - $21.9 Million
-80,013 Reduced 37.11%
135,626 $36.7 Million
Q4 2023

Feb 13, 2024

BUY
$164.52 - $238.84 $34.8 Million - $50.5 Million
211,414 Added 5003.88%
215,639 $51 Million
Q3 2023

Feb 15, 2024

BUY
$194.44 - $217.61 $41.5 Million - $46.4 Million
213,341 Added 4124.13%
218,514 $42.8 Million
Q2 2023

Feb 15, 2024

BUY
$183.71 - $210.25 $366,501 - $419,448
1,995 Added 62.78%
5,173 $1.09 Million
Q2 2023

Jul 28, 2023

SELL
$183.71 - $210.25 $13,227 - $15,138
-72 Reduced 1.68%
4,225 $888,000
Q1 2023

Feb 14, 2024

SELL
$191.89 - $259.92 $333,504 - $451,740
-1,738 Reduced 25.44%
5,093 $1.03 Million
Q1 2023

May 04, 2023

BUY
$191.89 - $259.92 $228,349 - $309,304
1,190 Added 38.3%
4,297 $867,000
Q4 2022

Feb 14, 2024

BUY
$197.11 - $250.07 $716,297 - $908,754
3,634 Added 113.67%
6,831 $1.49 Million
Q3 2022

Feb 15, 2024

SELL
$182.44 - $250.54 $38.8 Million - $53.2 Million
-212,461 Reduced 98.53%
3,178 $625,000
Q2 2022

Feb 14, 2024

BUY
$204.13 - $302.4 $45,929 - $68,040
225 Added 7.57%
3,197 $684,000
Q2 2022

Jul 26, 2022

BUY
$204.13 - $302.4 $27,557 - $40,824
135 Added 4.54%
3,107 $665,000
Q1 2022

Feb 14, 2024

SELL
$255.51 - $362.11 $16.6 Million - $23.5 Million
-65,014 Reduced 95.63%
2,972 $844,000
Q1 2022

May 06, 2022

SELL
$255.51 - $362.11 $16.6 Million - $23.5 Million
-65,014 Reduced 95.63%
2,972 $844,000
Q4 2021

Feb 14, 2024

SELL
$351.38 - $448.68 $51.9 Million - $66.2 Million
-147,653 Reduced 68.47%
67,986 $25.6 Million
Q4 2021

Feb 03, 2022

SELL
$351.38 - $448.68 $931,157 - $1.19 Million
-2,650 Reduced 3.75%
67,986 $25.6 Million
Q3 2021

Nov 10, 2021

BUY
$372.64 - $458.3 $23.3 Million - $28.7 Million
62,523 Added 770.65%
70,636 $29.1 Million
Q2 2021

Aug 11, 2021

BUY
$294.17 - $371.65 $2.39 Million - $3.02 Million
8,113 New
8,113 $3 Million

Others Institutions Holding CRL

About CHARLES RIVER LABORATORIES INTERNATIONAL, INC.


  • Ticker CRL
  • Exchange NYSE
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 50,863,300
  • Market Cap $9.56B
  • Description
  • Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Ass...
More about CRL
Track This Portfolio

Track Kbc Group Nv Portfolio

Follow Kbc Group Nv and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Kbc Group Nv, based on Form 13F filings with the SEC.

News

Stay updated on Kbc Group Nv with notifications on news.